EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Somatostatin analogs in neuroendocrine tumors with Ki‐67 index of ≥10%

Johanna Braegelmann, Annie Mathew, Boerge Schmidt, Hamza Kalisch, Wolfgang P. Fendler, Dagmar Führer‐Sakel, Harald Lahner

Journal of Neuroendocrinology · 2026-01 · 38 (1)

DOI: 10.1111/jne.70112 ↗
AbstractBibliografische Angaben

Abstract

Abstract Somatostatin analogs (SSAs) are an established first‐line therapy in intestinal and pancreatic neuroendocrine tumors (NETs). Based on Phase III studies, their use is recommended in NET with a Ki‐67 index of up to 10%. The effect of first‐line SSA therapy on differentiated NET with a Ki‐67 index ≥10% is poorly understood. This study aimed to investigate the outcomes of SSA therapy in differentiated NETs with a Ki‐67 index of ≥10%. A retrospective analysis of a prospectively created dataset of consecutive patients with NETs was performed. Patients with first‐line SSA monotherapy in advanced NET with a Ki‐67 index ≥10% were included. The study endpoints were progression‐free survival (PFS), overall survival (OS), and clinical benefit rate, defined as partial remission (PR) or stable disease (SD). Of 362 consecutive patients with a Ki‐67 index ≥10%, 67 received first‐line SSA therapy. The Ki‐67 index was 10–20% (G2) in 57 (85%) patients and >20% (G3) in 10 (15%). SD as the best response was reached in 40 (59.7%) patients and PR in 3 (4.5%), irrespective of the NET origin, time from the diagnosis, or somatostatin receptor‐based tracer uptake. The median PFS was 18 (95% confidence interval [CI], 5.7–30.3) months, and the median OS was 60 (95% CI, 38.2–81.8) months after the initiation of SSA therapy. Median PFS was significantly longer in patients with a Ki‐67 index of 10–20% (19 months; 95% CI, 6.2–31.8) compared to those with G3 NETs (6 months; 95% CI, 2.9–9.1; p = .015, log‐rank test), and in patients with a liver tumor burden of ≤10% (24 months; 95% CI, 12.7–35.3) versus >10% (4 months; 95% CI, 2.3–5.7; p = .007). First‐line SSA therapy can provide meaningful disease control in patients with G2 NETs and low tumor burden, despite a Ki‐67 index ≥10%. It may be a reasonable alternative to more intensive therapies in selected patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →